Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
SPRB Stock Chart & Stats
$127.00
--
Market closed
$127.00
--
Day’s Range― - ―
52-Week Range$4.32 - $240.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)988.68K
Market Cap
$111.83M
Enterprise Value-$11.35M
Total Cash (Recent Filing)$16.39M
Total Debt (Recent Filing)$1.82M
Price to Earnings (P/E)―
Beta-10.80
Next Earnings
Nov 17, 2025EPS Estimate
-13.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.50
Shares Outstanding1,065,672
10 Day Avg. Volume2,922,716
30 Day Avg. Volume988,676
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.04
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-8.74
Enterprise Value/Gross Profit-8.74
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$207.00Price Target Upside62.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StrategyRaising the price target to $10 to reflect a reverse stock split, indicating increased confidence in the company's future performance.
Market PotentialTA-ERT could become the first-to-market therapy for MPS IIIB, which is encouraging for investors.
Regulatory ApprovalsThe granting of FDA Breakthrough Therapy Designation for TA-ERT has boosted investor confidence and driven the stock higher.
Bears Say
Pricing ConcernsUncertainty remains regarding the drug's pricing and market opportunity for this ultra-rare indication.
Spruce Biosciences News
SPRB FAQ
What was Spruce Biosciences’s price range in the past 12 months?
Spruce Biosciences lowest stock price was $4.32 and its highest was $240.00 in the past 12 months.
What is Spruce Biosciences’s market cap?
Spruce Biosciences’s market cap is $111.83M.
When is Spruce Biosciences’s upcoming earnings report date?
Spruce Biosciences’s upcoming earnings report date is Nov 17, 2025 which is in 8 days.
How were Spruce Biosciences’s earnings last quarter?
Spruce Biosciences released its earnings results on Aug 14, 2025. The company reported -$3.5 earnings per share for the quarter, beating the consensus estimate of -$18 by $14.5.
Is Spruce Biosciences overvalued?
According to Wall Street analysts Spruce Biosciences’s price is currently Undervalued.
Does Spruce Biosciences pay dividends?
Spruce Biosciences does not currently pay dividends.
What is Spruce Biosciences’s EPS estimate?
Spruce Biosciences’s EPS estimate is -13.94.
How many shares outstanding does Spruce Biosciences have?
Spruce Biosciences has 1,065,672 shares outstanding.
What happened to Spruce Biosciences’s price movement after its last earnings report?
Spruce Biosciences reported an EPS of -$3.5 in its last earnings report, beating expectations of -$18. Following the earnings report the stock price went up 2.971%.
Which hedge fund is a major shareholder of Spruce Biosciences?
Among the largest hedge funds holding Spruce Biosciences’s share is Aisling Capital Management LP. It holds Spruce Biosciences’s shares valued at 0.
Spruce Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$207.00 (62.99% Upside)
$207.00 (62.99% Upside)
Hedge Fund Trend
Decreased
By 16.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $667.1 over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 6.8%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
312.60%
12-Months-Change
Fundamentals
Return on Equity
-133.62%
Trailing 12-Months
Asset Growth
-71.11%
Trailing 12-Months
Company Description
Spruce Biosciences
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
SPRB Stock 12 Month Forecast
Average Price Target
$207.00
▲(62.99% Upside)